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Radiotherapy (RT) is a localized therapy that is highly
effective in killing primary tumor cells located within
the field of the radiation beam. We present evidence
that irradiation of breast tumors can attract migrating
breast cancer cells. Granulocyte-macrophage col-
ony stimulating factor (GM-CSF) produced by tumor
cells in response to radiation stimulates the recruit-
ment of migrating tumor cells to irradiated tumors,
suggesting a mechanism of tumor recurrence after
radiation facilitated by transit of unirradiated, viable
circulating tumor cells to irradiated tumors. Data
supporting this hypothesis are presented through
in vitro invasion assays and in vivo orthotopicmodels
of breast cancer. Our work provides amechanism for
tumor recurrence in which RT attracts cells outside
the radiation field to migrate to the site of treatment.INTRODUCTION
Over 200,000 breast cancers are diagnosed every year in the
United States (American Cancer Society, 2013). One-third of all
breast cancer patients will suffer local recurrence after their initial
treatment. The addition of radiotherapy (RT) to breast cancer
treatment regimens has been demonstrated in numerous trials
to reduce the rate of local recurrence (Whelan et al., 2010). How-
ever, there remains concern over the persistence of in-field re-
currences, particularly in aggressive tumors such as triple-nega-
tive breast cancer (Abdulkarim et al., 2011). Radiation is known
to exert both short- and long-term biological effects beyond
simply killing tumor cells. On the microscopic scale, radiation
alters blood vessel permeability and integrity early after treat-
ment (Dewhirst et al., 1990). The benefits of RT to breast cancer
patients generally outweigh the side effects of this procedure in
normal tissue, but it is critical to understand the full spectrum of
radiation effects so that this therapy can be optimally applied.
Circulating tumor cells (CTCs) have been identified in the pe-
ripheral blood of breast cancer patients. Previous studies have
proposed that the levels of CTCs can be a predictor of outcome
(Cristofanilli et al., 2004). Although CTC burden does not corre-
late with the size of the primary tumor (Hu¨semann et al., 2008),402 Cell Reports 8, 402–409, July 24, 2014 ª2014 The Authorsit has been observed that the number of CTCs present in the
blood is indicative of an unfavorable prognosis for both tumor
recurrence and metastasis in breast cancer patients (Graves
and Czerniecki, 2011). It has also been shown that CTCs can re-
turn to and colonize their tumors of origin in addition to seeding
metastasis in distant organs, in a process that has been termed
tumor self-seeding. Tumor self-seeding has been shown to be
mediated by both CTC attraction to the parent tumor and the
infiltrative properties of the CTC itself (Kim et al., 2009; Norton
and Massague´, 2006). This process has been postulated to
contribute to tumor aggressiveness, since CTCs can survive
and proliferate in the supportive environment of a primary tumor
more so than in a foreign tissue type.
The relationship between tumor self-seeding and anticancer
therapies has not yet been investigated. Because of the focal
nature of RT, we hypothesized that transit of tumor cells outside
the radiation field at the time of treatment back to the primary
tumor may provide a previously unconsidered mechanism of
tumor regrowth. The aim of this study was to assess the inci-
dence of tumor cell migration in the context of RT and specifically
to evaluate whether radiation influences this process.
RESULTS
Radiation Increases Tumor Cell Invasion, but Not Cell
Growth, In Vitro
To investigate the effects of cell irradiation on invasion in vitro, we
performed transwell invasion assays using conditionedmedia as
an attractant, harvested from cells treated with different doses of
radiation. Both murine (4T1) and human (A549, A375, and MDA-
MB-231) cell lines showed an increase in cell invasion (Figures 1A
and 1B) toward media collected after irradiation to a dose of 20
Gy. We observed differences in the number of invading cells
based on the time of supernatant (SN) collection postirradiation
and the cell type (data not shown). When we applied different
radiation doses and performed invasion assays using the har-
vested SN, we observed a dose-threshold effect in the number
of invading cells between doses from 0 to 5Gy but no difference
with higher doses (Figures 1C and 1D). In vitro cell proliferation
measurements using control and irradiated (IR) SN did not
show any significant difference in cell growth induced by IR SN
(Figures 1E and 1F). Taken together, these results suggest that
radiation induces the production of a secreted factor that attracts
tumor cells but does not affect cell proliferation.
Figure 1. Supernatant from Irradiated Cells
Promotes Cell Invasion, but Not Cell Prolif-
eration, in Both Murine and Human Cell
Lines
(A) Transwell migration assays using supernatant
(SN) from a murine breast cancer cell line (4T1)
collected 2 days after irradiation (IR) to a dose of
0 Gy (non-IR) or 20 Gy (IR).
(B) Transwell migration assays using SN from
human lung (A549), melanoma (A375), and breast
cancer cells (MD-MB-231) collected 7 days after
IR to a dose of 0 Gy (non-IR) or 20 Gy (IR).
(C and D) Transwell migration assays using SN
from 4T1 and MDA-MB-231 cells treated with
increasing doses of radiation (0, 5, 10 and 20Gy).
(E and F) Proliferation of 4T1 and MDA-MB-231
cells grown with SN from control and IR cells,
respectively.
Scale bars represent 100 mm (*p < 0.05, **p < 0.01,
***p < 0.001). Error bars represent SD.Radiation Enhances Tumor Cell Recruitment In Vivo
To study the effects of radiation on tumor cell migration in vivo,
tumors were grown in mice using mouse mammary carcinoma
4T1 and luciferase-expressing 4T1 (4T1-luci) cell lines and the
human breast adenocarcinoma MDA-MB-231 and luciferase-
expressing MDA-MB-231 (MDA-MB-231-luci) cell lines. The
parental and labeled cell lines were injected into contralateral
mammary fat pads in order to create a bioluminescent ‘‘donor’’
tumor and an unlabeled ‘‘recipient’’ tumor (Figure 2A). The recip-
ient tumors in one group of mice were treated with a single dose
of 20 Gy, with another group of mice with equivalent tumors
acting as unirradiated controls (non-IR). A 3.2 mm lead shield
was used to conform radiation to the targeted recipient tumor
while sparing the donor tumor and other tissues (Li et al.,
2011). After sacrificing the mouse and excising the recipient
tumor at 10 days postirradiation, ex vivo bioluminescence imag-
ing (BLI) was performed. A significant increase in the number of
photons released from IR recipient 4T1 tumors (n = 22) was
observed relative to non-IR control 4T1 (n = 20) (Figures 2B
and S1F), indicating an increased number of labeled tumor cells
invading the IR tumors. When only an unlabeled recipient tumor
was injected into the mammary fat pad, followed by an intrave-
nous (i.v.) injection of labeled cells, we also observed a signifi-
cant increase of light photons from the IR recipients (Figure 2D).
The kinetics of this CTC recruitment by IR tumors was studied
by harvesting tumors at different time points after irradiation of
the recipient to a dose of 20 Gy (Figure 2E). In the 4T1 tumorCell Reports 8, 402–model, radiation-induced tumor reseed-
ing is initially minimal but increases to a
measured maximum at 10 days postirra-
diation. To investigate the dose de-
pendence of this process, the recipient
tumors were treated with doses up to
20 Gy and ex vivo BLI was performed
10 days after treatment (n = 5 for dose)
(Figure 2F). We observed statistically sig-
nificant differences between the non-IRtumors and the tumors IR to doses of 10, 15, and 20 Gy; how-
ever, this effect appears to plateau for doses of 10 Gy and higher
as also shown in vitro.
These experiments were repeated in analogous model sys-
tems employing the human MDA-MB-231 cell line (Figure 2C).
As in the 4T1model, there was an increase in the number of pho-
tons released from the IR recipient tumor relative to the control
tumor. This difference was statistically significant, although the
magnitude of the difference was less pronounced than in the
4T1 model, consistent with the relative results obtained in vitro
for these cell lines (Figure 1). These data demonstrate that irradi-
ation of a tumor in vivo stimulates the recruitment of migrating
cancer cells after a dose threshold.
GM-CSF Is Overexpressed after Irradiation in Both
Human and Murine Tumor Cell Lines
To identify the factor(s) responsible for the increase in tumor cell
recruitment after IR, we probed the SN of 4T1 cells collected
2 days after irradiation to doses up to 20Gy to evaluate the levels
of 62 secreted cytokines (Figures 3A, S2, and S3). Within this
panel of cytokines, radiation increases were observed in granu-
locyte-macrophage colony-stimulating factor (GM-CSF). West-
ern blots of SN from 4T1 and MDA-MB-231 cells confirmed
that the secretion of GM-CSF is increased in response to radia-
tion (Figures 3B and 3D). A panel of SN from cells treated with
lower doses showed a threshold in the amount of expression
of GM-CSF between 4 and 5 Gy, which then was stable at higher409, July 24, 2014 ª2014 The Authors 403
Figure 2. Seeding of Tumors by Migrating Tumor Cells Is Enhanced by Irradiation In Vivo in Both Murine and Human Tumor Models
(A) Schematic of the donor-recipient experimental protocol.
(B) Ex vivo bioluminescence images of 20 Gy irradiated (IR) and unirradiated (non-IR) 4T1 recipient tumors from two representative mice from each group.
Quantification of the ex vivo bioluminescence images from 22 IR 4T1 recipient tumors and 20 non-IR 4T1 recipient tumors. Values are represented on a loga-
rithmic scale.
(C) Ex vivo bioluminescence images of IR and non-IR MDA-MB-231 recipient tumors from 2 representative mice from each group. Quantification of the images in
from 5 IR MDA-MB-231 recipient tumors and 5 non-IR MDA-MB-231 recipient tumors.
(D) Ex vivo bioluminescence images of non-IR and 20Gy IR 4T1 recipient tumors 10 days after intravenous injection of 4T1-luci cells. Quantification of the images
in from 5 IR 4T1 recipient tumors and 5 non-IR 4T1 recipient tumors.
(E) Quantification of photons released from ex vivo BLI of 4T1 recipient tumors IR or non-IR after 0, 5, and 10 days (n = 5 mice per group).
(F) Quantification of ex vivo BLI of 4T1 recipient tumors 10 days after treatment with a variety of radiation doses (0, 2, 10, 15, and 20 Gy) (n = 5 mice per group).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0005. Error bars represent SD.
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Figure 3. GM-CSF Is Overexpressed after Irradiation in Both Human and Murine Cell Lines
(A) Membranes from cytokine arrays probed with SN from 4T1 cells IR to doses of 0, 5, 10, or 20 Gy and its quantification.
(B) Western blot (WB) for GM-CSF and IL-8 from SN from 4T1 cells IR to doses of 0, 5, 10, and 20 Gy and its quantification relative to total protein loaded
(Ponceau).
(C) GM-CSF WB from 4T1 IR SN with lower doses (0, 1, 2, 3, 4, 5, 10, 15, and 20 Gy). Quantification is relative to the total protein loaded.
(D)WB analysis for GM-CSF and IL-8 in the SN ofMDA-MB-231 cells treated with different doses (0, 5, 10, and 20Gy) and its quantification relative to total protein
loaded.
(E) ELISA analysis of GM-CSF in SN of 4T1 and MDA-MB-231 IR cells with different doses (0, 5, 10, and 20 Gy).
(F) ELISA analysis of GM-CSF in the serum of mice bearing IR and control orthotopic 4T1 tumors.
See also Figures S2 and S3. Error bars represent SD.doses (Figure 3C). Furthermore, ELISA analysis of the IR SN
confirmed the increase of GM-CSF expression in both 4T1 and
MDA-MB-231 cell lines (Figure 3E). Thus, the level of induction
of GM-CSF correlates with the level of increase in tumor cell
migration seen for 4T1 and MDA-MB-231 cells in Figures 1 and
2. Increased GM-CSF was also detected by ELISA in the serum
of tumor-bearing mice treated with radiation as compared to
untreated controls, indicating that this effect occurs in vivo and
that the GM-CSF enters the circulation (Figure 3F).Silencing of GM-CSF Inhibits Cell Invasion In Vitro and
Tumor Self-Seeding In Vivo
To investigate the role of GM-CSF in cell invasion and tumor cell
migration after IR, knockdown (KD) 4T1 clones were obtained
after transfection with small hairpin RNA (shRNA) constructs
targeting GM-CSF (Figure 4A). The in vitro growth rate of cells
expressing these constructs was not significantly different from
that of parental cells (Figure S1C). The role of GM-CSF in inva-
sion was evaluated through transwell assays using SN collectedCell Reports 8, 402–409, July 24, 2014 ª2014 The Authors 405
Figure 4. GM-CSF Promotes Cell Invasion In Vitro and Tumor Seeding In Vivo
(A) Western blot analysis of GM-CSF in 4T1 and MDA-MB-231 cells after transfection with an shRNA targeting GM-CSF.
(B) Transwell migration assay of 4T1 WT cells toward SN collected from 4T1 WT, 4T1 shRNA GFP, and 4T1 shRNA GM-CSF clones.
(C) Transwell migration assay using GM-CSF KD 4T1 cells and 4T1 shRNA GFP cells. SN from control or IR 4T1WT cells was used as chemoattractant. GM-CSF
neutralizing antibody or recombinant GM-CSF protein was added to IR and control SN.
(D) Transwell migration assay using GM-CSF KD MDA-MB-231 cells and MDA-MB-231 shRNA GFP cells. SN from IR MDA-MB-231 WT cells was used as
chemoattractant and GM-CSF neutralizing antibody was added.
(E) Ex vivo bioluminescence images and corresponding quantification for recipient tumors IR to a dose of 0 or 20 Gy fromWT, shGFP-expressing, or shGM-CSF-
expressing 4T1 cells.
(F) Tumor growth curves from 4T1 shGFP-expressing and 4T1 shGM-CSF clones (#19 and #22) after 0 or 10 Gy irradiation.
(G) Ex vivo bioluminescence images and corresponding quantification of recipient tumors IR to a dose of 0 or 10 Gy, after subsequent intravenous delivery of 4T1-
luci cells, from WT, shGFP-expressing, or shGM-CSF-expressing 4T1 cells.
(H) Clonogenic survival of 4T1 shRNA GFP and 4T1 GM-CSF KD clones after RT.
(I) A model of baseline and radiation-induced tumor reseeding.
Scale bars represent 100 mm (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0005). Error bars represent SD.
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from the different silenced clones. A clear relationship between
the level of GM-CSF in the SN and cell invasion was observed
(Figure 4B). When these KD cells were used as invading cells
toward control or IR SN, no significant difference was observed
when compared to parental cells (Figure 4C). Adding recombi-
nant GM-CSF to the control medium was sufficient to stimulate
invasion of 4T1 cells and KD clones (Figure 4C). We also investi-
gated the use of neutralizing antibody added to the IR SN, which
produced a large decrease in cell invasion in both 4T1 andMDA-
MB-231 cells (Figures 4C, 4D, S1D, and S1E). GM-CSF is there-
fore necessary and sufficient to induce tumor cell invasion
in vitro.
To determine whether GM-CSF plays a role in tumor recruit-
ment, we conducted an in vivo donor/recipient experiment.
The donor was a 4T1-luci tumor, while the recipient was grown
from 4T1 wild-type (WT), 4T1-shGM-CSF (clone #19) or 4T1-
shGFP cells. A portion of the recipient tumors of each type
was treated to a single dose of 20 Gy, while others were kept
as controls. We observed the same degree of ex vivo BLI signal
in the 4T1-WT and 4T1-shGFP recipient tumors and the same
increase in signal in these tumors after irradiation. However,
seeding of 4T1-shGM-CSF recipient tumors was significantly
reduced relative to the 4T1-WT recipient tumors (Figure 4E).
This was true for both the IR and non-IR recipients. Moreover,
no significant stimulation of tumor cell recruitment by radiation
was observed in the 4T1-shGM-CSF tumors. While the differ-
ence between IR and non-IR tumors from each cell type was
very evident, there was no significant difference in final tumor
volume when comparing each condition (IR and non-IR) within
the different tumor types (Figure S1G). Using the single recipient
tumor and i.v. donor cell delivery model, we found that regrowth
of the recipient tumor after a single dose of 10 Gy was signifi-
cantly inhibited in the GM-CSF KD clones relative to the 4T1
shRNA GFP control (Figures 4F and 4G). No corresponding dif-
ference in intrinsic cell radiosensitivity was observed between
these cells in vitro (Figure 4H). These findings demonstrate the
necessity of GM-CSF in the stimulation of tumor cell migration
and recruitment by radiation.
DISCUSSION
Tumor self-seeding has been demonstrated in models of breast,
colon, and skin cancer (Kim et al., 2009). We found that in pre-
clinical models of breast cancer, irradiation of a tumor provokes
a significant increase in seeding by tumor cells migrating from
another preexisting tumor. Similarly, we observed an enhance-
ment in seeding of IR tumors when CTCs were introduced
directly into the circulation by i.v. injection, suggesting that this
effect is not specific to the mechanism of introduction of
CTCs. Our findings agree with previous studies that have shown
that sublethal doses of irradiation can promote migration and
invasiveness of breast (Paquette et al., 2013), glioma (Wild-
Bode et al., 2001), pancreas (Qian et al., 2002), liver (Zhou
et al., 2012), and melanoma (Rofstad et al., 2004) cancer cells.
These previous studies, however, relied primarily on in vitro ex-
periments and employed in vitro preirradiation prior to tumor
inoculation in an animal when performing in vivo studies. Clini-
cally, it has recently been demonstrated for the first time thatsublethal doses of RT result in mobilization of viable CTCs into
the circulation of patients with non-small cell lung cancer (Martin
et al., 2014), which highlights the need to further monitor the
behavior of CTCs during RT. The aim of this study was to repli-
cate the clinical situation where a patient has a primary tumor
and a burden of CTCs, which in our model were produced either
by another preexisting tumor or through direct i.v. injection.
While the presence of metastasis generally limits patient
outcome more so than control of the primary tumor by radiation,
it is important to note that migrating tumor cells may exist in the
absence of secondary lesions and that occult metastatic cells
may lay dormant, in a growth-arrested state, for months or years
(Schmidt-Kittler et al., 2003). Under these circumstances,
patients without frank metastatic disease may be susceptible
to radiation-induced tumor cell reseeding and subsequent
recurrence.
We observed an increase in the rate of invasion of cells toward
the SN of IR cells above a threshold dose of approximately 4 Gy
in vitro, suggesting that the factors produced in response to irra-
diation may serve as chemoattractants. From a cytokine array,
we observed that GM-CSF was overexpressed in the SN of
4T1 cells after irradiation. Dose- and time-dependent increases
in the expression of GM-CSF by human fibroblasts in response
to irradiation have been reported, in which expression is regu-
lated at both the transcriptional and posttranscriptional levels
(Hachiya et al., 1994). More recent studies have also demon-
strated that GM-CSF is expressed in the skin after irradiation
(Mu¨ller and Meineke, 2007). SN from 4T1 cells in which GM-
CSF has been knocked down had a diminished ability to provoke
cell invasion in vitro and tumor recruitment in vivo, suggesting
that GM-CSF acts as a paracrine signal in this model to attract
CTCs to an IR tumor.
GM-CSF is administered to patients clinically under the trade
name Leukine to stimulate production of white blood cells during
fungal infections (Safdar, 2007), Crohn disease (Korzenik et al.,
2005), bone marrow transplant, and chemotherapy (Hsu and
Link, 2012). The data presented here demonstrate that overex-
pression of GM-CSF recruits CTCs to IR tumors. A similar para-
crine function of this factor was described in a study in which a
panel of cytokines including GM-CSF produced by both MDA-
MB-231 and MCF-7 cells attracted adipose tissue-derived
mesenchymal stem cells (AMSCs) toward the tumor microenvi-
ronment (Senst et al., 2013). These same AMSCs were also
induced to migrate toward conditioned media of both MDA-
MB-231 and 4T1 cells (Gehmert et al., 2010).
It is important to note that tumor cell migration toward media
from non-IR cells as well as toward non-IR tumors was observed
in this study. This suggests that radiation is not necessary for
cancer cells to home to primary tumors, but that it stimulates
this process. We propose that different cytokines may mediate
tumor seeding under normal conditions, such as interleukin-6
(IL-6) and IL-8 (Kim et al., 2009), and in response to genotoxic
stress, such as GM-CSF, identified here. IL-6 and IL-8, along
with baseline levels of GM-CSF, may promote tumor cell migra-
tion in the pretreatment setting, while increases in GM-CSF
levels give rise to the increase in this process after RT (Figure 4I).
This model is supported by the present observations that radia-
tion did not modulate levels of IL-6 or IL-8 in vitro and that KD ofCell Reports 8, 402–409, July 24, 2014 ª2014 The Authors 407
GM-CSF inhibited tumor seeding both with and without
radiation.
Tumor self-seeding has been shown to involve factors in both
the recruiting tumor and the CTCs. In this work, we focused on
the chemoattractive ability of the primary tumor and the mecha-
nisms by which radiation may modulate it. However, the inci-
dence of radiation-induced tumor seeding in the 4T1 and
MDA-MB-231 models studied here is associated with the
aggressiveness of each of these tumor systems. The 4T1 model
is extremely aggressive and metastatic, resulting in widespread
metastasis and mouse death within a month of orthotopic inoc-
ulation, while the MDA-MB-231 is slower growing. This observa-
tion highlights the role of the CTCs in this process, in addition to
that of the primary tumor (Kim et al., 2009). In addition, it is known
that accelerated repopulation occurs after RT, and this may be
exacerbated in the case of unirradiated CTCs infiltrating an irra-
diated tumor. However, the sensitivity of this process to KD of
GM-CSF indicates that recruitment of CTCs and not proliferation
is the critical aspect of this process.
Triple-negative breast cancers exhibit increased local and
distant recurrence after treatment (Dent et al., 2007). This may
be due in part to a propensity for tumor self-seeding, because
of both the aggressiveness of this disease and the presence of
CTCs, and in part to the stimulation of CTCs migration by radia-
tion as shown here. Clinical studies evaluating this hypothesis
are complicated by the lack of technology to track CTCs in vivo.
Further work is needed to evaluate the association between clin-
ically measurable variables including CTC number, GM-CSF
levels, exogenously administered GM-CSF, and tumor recur-
rence. In addition, the development of therapies blocking the
effects of radiation-induced overexpression of GM-CSF, such
as neutralizing antibodies, may be of great clinical interest in
order to minimize recruitment of CTCs to the primary tumor after
RT. Finally, the sensitivity of this process to fractionated RT reg-
imens should be investigated.
EXPERIMENTAL PROCEDURES
Cell Culture
Human lung (A459), melanoma (A375), and breast cancer (MDA-MB-231) cell
lines and a mouse breast cancer cell line (4T1) were grown following ATCC
specifications (American Type Culture Collection). 4T1 andMDA-MB-231 cells
were transduced with retrovirus particles encoding for the expression of firefly
luciferase gene (FLuc) and with retroviruses produced from mouse shRNA
clones targeting GM-CSF gene (TRCN0000054618, TRCN0000054619,
TRCN0000054620, TRCN0000054621, and TRCN0000054622) (Thermo
Scientific). A vector encoding shRNAGFPwas used as a control. FLuc expres-
sion was determined both in vivo and in vitro (Figures S1A and S1B).
Transwell Invasion Assays
A total of 13 106 cells of each cell typewere plated on a 10 cmdish and IR with
different doses using a cesium source. Media from IR cells was collected at
different time points and used as conditioned media in transwell migration
assays (BD Biocat Matrigel Invasion Chamber). A total of 1 3 105 cells were
placed in the upper chamber of the transwell setup.
Cytokine Antibody Array
Proteins secreted from 4T1 cells were probed using mouse cytokine antibody
arrays (Mouse Cytokine Antibody Array 3, Raybiotech), using conditioned
media from IR and non-IR cells. All the steps were done according to the man-
ufacturer’s protocols.408 Cell Reports 8, 402–409, July 24, 2014 ª2014 The AuthorsAnimal Studies
All animal experiments were done according to a protocol approved by the
institutional animal care and use committee. Seven-week-old nude female
mice (Charles River Laboratories) were inoculated with 5 3 104 4T1 and 5 3
104 4T1-luci cells or 1 3 106 MDA-MB-231 and 1 3 106 MDA-MB-231-luci
cells, suspended in 50 ml of PBS, in contralateral mammary glands. Once
tumors reached 7 mm, the unlabeled tumor was IR to a dose from 0 to 20
Gy. IR was performed using a 225 kVp cabinet X-ray system filtered with
0.5 mmCu. Animals were anesthetized and placed under a 3.2 mm lead shield
with 1 cm circular apertures where the tumors were placed. Ex vivo BLI was
performed 10 days after IR for the 4T1 tumor model or 20 days for the MDA-
MB-231 tumor model. Animals were injected with 100 mg/g of D-luciferin,
and the unlabeled 4T1 tumor was excised. Tumors were imaged using an
IVIS 200 (PerkinElmer).
Western Blot
For protein detection, cell supernatant was collected and concentrated with
Ultracel-3K centrifugal filters (EMD Millipore). A total of 10 mg of protein was
separated using a 12% SDS-PAGE gel and further detected with a GM-CSF
antibody (Lifespan BioSciences) and a CXCL8/IL-8 antibody (R&D Systems).
Clonogenics
4T1 shRNA GFP and 4T1 shRNA GM-CSF (clones 19 and 22) cells were IR up
to 10 Gy using a cesium source and plated in 6 cm dishes at appropriate
concentrations. After 12 days, colonieswere stained and counted. The survival




Statistical significance was evaluated using an unpaired Student’s t test to
compare two different groups and one-way nonparametric ANOVA test,
accounting for multiple comparisons using the Tukey method, to compare
multiple doses or conditions.
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